Advanced Hepatocellular Carcinoma: Benefits of Atezolizumab and Bevacizumab in Clinical Practice. Case Report

Authors

DOI:

https://doi.org/10.22516/25007440.1304

Keywords:

Hepatocellular Carcinoma, immunotherapy, tyrosine kinase inhibitors

Abstract

Background: Hepatocellular carcinoma (HCC), originating from hepatocytes, ranks as the sixth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Treatment options include surgical resection, locoregional therapies, systemic therapy, and liver transplantation, depending on disease stage.

Case report: We describe a 78-year-old male with multiple comorbidities diagnosed with stage IIIB hepatocellular carcinoma according to the BCLC B classification. He was treated with atezolizumab and bevacizumab, achieving a favorable response with tumor marker negativization and stable disease.

Discussion: Since 2008, HCC treatment has undergone substantial progress. Earlier systemic therapies such as sorafenib and lenvatinib offered response rates around 24% and overall survival of up to 13 months. Current therapies have demonstrated significantly improved outcomes. Notably, the phase III IMbrave150 trial (2020) showed the advantages of combining immunotherapy with antiangiogenic agents over sorafenib in patients with advanced HCC, with overall survival reaching up to 89%.

Downloads

Download data is not yet available.

Author Biographies

Erick Andrés Cantor Rizo, Fundación Santa Fe de Bogotá

Internist, Clinical Hemato-Oncologist, Hospital Universitario Fundación Santa Fe de Bogotá. Bogotá, Colombia. 

Andrés Felipe Bejarano Ramírez, Fundación Santa Fe de Bogotá

General Practitioner, Hospital Universitario Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Zamira Fernanda Gómez Giraldo, Hospital Universitario Fundación Santa Fe de Bogotá

General Practitioner, Hospital Universitario Fundación Santa Fe de Bogotá. Bogotá, Colombia.

John Alejandro Murillo Silva, Fundación Santa Fe de Bogotá

General Practitioner, Hospital Universitario Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Henry Alexander Vargas Díaz, fundacion

Internist, Clinical Oncologist, Hospital Universitario Fundación Santa Fe de Bogotá. Bogotá, Colombia.

Mónica Lorena Tapias Mantilla, Fundación Santa Fe de Bogotá

Internist, Hepatologist, Hospital Universitario Fundación Santa Fe de Bogotá. Bogotá, Colombia.

References

Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1-61. https://doi.org/10.1016/bs.acr.2020.10.001

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604. https://doi.org/10.1038/s41575-019-0186-y

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet (London). 2022;400(10360):1345-62. https://doi.org/10.1016/S0140-6736(22)01200-4

Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023;27(1):85-102. https://doi.org/10.1016/j.cld.2022.08.004

Sim HW, Knox J. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer. 2018;42(1):40-8. https://doi.org/10.1016/j.currproblcancer.2017.10.007

Finn RS, Ducreux M, Qin S, Galle PR, Zhu AX, Ikeda M, et al. IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2018;36(15_suppl):TPS4141-TPS4141. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS4141

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: Patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6(8):649-58.

Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113-22. https://doi.org/10.1007/s00535-019-01642-1

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862-73. https://doi.org/10.1016/j.jhep.2021.11.030

Figura 1. A. Resonancia magnética (RM): existencia de una masa sólida con contenido heterogéneo en los segmentos VII y VIII de los lóbulos hepáticos derechos. B. Tomografía por emisión de positrones (PET). Se observó un aumento focal en la captación en el lóbulo hepático derecho, correspondiente al segmento 6/7. Imágenes propiedad de los autores.

Published

2025-12-23

How to Cite

Cantor Rizo, E. A., Bejarano Ramírez, A. F., Gómez Giraldo, Z. F., Murillo Silva, J. A., Vargas Díaz, H. A., & Tapias Mantilla, M. L. (2025). Advanced Hepatocellular Carcinoma: Benefits of Atezolizumab and Bevacizumab in Clinical Practice. Case Report. Revista Colombiana De Gastroenterología, 40(4), 497–501. https://doi.org/10.22516/25007440.1304

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views639
Galley views326
PDF Views246
HTML views0
Other views80

Some similar items: